Dyne Therapeutics will present five clinical and research presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, highlighting advances across its neuromuscular disease portfolio. The presentations will feature new cardiopulmonary function data from the DELIVER trial evaluating z-rostudirsen in Duchenne muscular dystrophy (DMD), as well as Phase 3 trial design details for z-basivarsen in myotonic dystrophy type 1 (DM1).
The company's FORCE platform, which employs modular antisense oligonucleotide technology, represents a systematic approach to addressing multiple neuromuscular conditions. The presentations span three disease indications, demonstrating the platform's breadth and the clinical development progress Dyne has achieved across its pipeline.
These disclosures reflect the company's advancement toward later-stage clinical trials and provide the scientific community with detailed insights into safety, efficacy, and study design across its lead programs in rare neuromuscular diseases.